BioRestorative Therapies, Inc., a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders. Its disc/spine program (brtxDisc) includes a lead cell therapy candidate, BRTX-100, a product candidate formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow, which has completed Phase …
Over the last 12 months, insiders at BioRestorative Therapies, Inc. have bought $470,956 and sold $2,752 worth of BioRestorative Therapies, Inc. stock.
On average, over the past 5 years, insiders at BioRestorative Therapies, Inc. have bought $527,029 and sold $11,518 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Broadrick Dale (10 percent owner) — $460,727. Silva Francisco (VP of Research and Development) — $10,229.
The last purchase of 6,600 shares for transaction amount of $8,250 was made by Silva Francisco (VP of Research and Development) on 2024‑04‑09.
2024-10-28 | Sale | 10 percent owner | 1,112 0.0157% | $1.58 | $1,757 | 0.00% | ||
2024-04-09 | VP of Research and Development | 6,600 0.0952% | $1.25 | $8,250 | +19.53% | |||
2024-04-08 | VP of Research and Development | 1,708 0.0228% | $1.16 | $1,979 | +19.53% | |||
2024-02-09 | 10 percent owner | 86,041 1.4895% | $1.32 | $113,574 | +4.81% | |||
2024-02-08 | 10 percent owner | 157,585 2.6821% | $1.30 | $204,508 | +10.16% | |||
2024-02-08 | 10 percent owner | 73,959 1.2124% | $1.25 | $92,449 | +10.16% | |||
2024-02-07 | 10 percent owner | 36,374 0.6583% | $1.38 | $50,196 | -0.70% | |||
2023-12-01 | Sale | 10 percent owner | 250 0.0053% | $1.88 | $469 | -18.62% | ||
2023-11-27 | Sale | 10 percent owner | 278 0.0059% | $1.89 | $525 | -19.47% | ||
2023-09-15 | 10 percent owner | 10,000 0.213% | $1.66 | $16,600 | -3.89% | |||
2023-09-15 | President, CEO, COB | 2,200 0.048% | $1.70 | $3,740 | -3.89% | |||
2023-09-14 | 10 percent owner | 10,000 0.2062% | $1.54 | $15,400 | +0.47% | |||
2023-09-13 | President, CEO, COB | 800 0.0161% | $1.53 | $1,226 | +7.00% | |||
2023-09-07 | 10 percent owner | 2,000 0.044% | $1.86 | $3,720 | -14.81% | |||
2023-09-06 | President, CEO, COB | 2,887 0.0638% | $1.96 | $5,659 | -15.13% | |||
2023-08-31 | VP of Research and Development | 4,954 0.1071% | $2.22 | $10,998 | -26.36% | |||
2023-07-28 | 10 percent owner | 500 0.016% | $2.89 | $1,445 | -41.05% | |||
2023-07-27 | 10 percent owner | 1,000 0.031% | $2.80 | $2,800 | -33.68% | |||
2023-07-25 | President, CEO, COB | 4,200 0.1134% | $2.44 | $10,248 | -30.45% | |||
2023-03-31 | VP of Research and Development | 747 0.0216% | $3.56 | $2,659 | -42.79% |
Broadrick Dale | 10 percent owner | 445933 6.4442% | $1.62 | 79 | 4 | <0.0001% |
Silva Francisco | VP of Research and Development | 155759 2.2509% | $1.62 | 21 | 1 | <0.0001% |
Westbury Trust | 10 percent owner | 3115000 45.015% | $1.62 | 1 | 0 | |
Desmarais John M | 455000 6.5752% | $1.62 | 2 | 0 | ||
ALSTODT LANCE | President, CEO, COB | 189505 2.7385% | $1.62 | 33 | 0 | <0.0001% |